New Phase 3 Study Shows that Gazyva® (obinutuzumab) Significantly Reduces Lupus Disease Activity in SLE
A new Phase 3 study published in the New England Journal of Medicine found that Gazyva® (obinutuzumab) significantly reduced disease...
New England Journal of Medicine
LRA Applauds GSK on Positive Phase 3 Study of Benlysta® in Lupus Nephritis
September 16, 2020
NEW YORK, NY. The Lupus Research Alliance welcomes positive BLISS-LN Phase 3 data published in this week’s...
Positive Results on Anifrolumab for Lupus Published in New England Journal of Medicine
December 18, 2019
The Lupus Research Alliance (LRA) welcomes additional positive results published today in the New England Journal of...